Gallotta E S, Sironi M, Spreafico F, Vecchi A
Eur J Cancer Clin Oncol. 1986 Jun;22(6):637-45. doi: 10.1016/0277-5379(86)90160-4.
The immune effects of Elliptinium (2-methyl-9-hydroxyellipticinium, 9-HME), a chemical recently shown to possess clinical antineoplastic activity, were investigated in mice. Primary antibody responses to T-dependent and T-independent antigens, DTH reactivity and responsiveness to mitogens were significantly depressed only by post treatment with single drug doses of at least 5 mg/kg i.v., i.e. doses clearly above those known to exert full antitumoral effectiveness and to induce lymphoid cell depletion in the same species. Only drug doses in the LD50 range (i.e. 10 mg/kg) reduced the capacity of NK cells and of activated macrophages to express non-specific cytotoxicity towards tumor target cells. When repeated dose regimens were used, significant immune depression was again seen at doses above those displaying chemotherapeutic activity. Data obtained suggest that at chemotherapeutically effective dosages 9-HME possesses in mice a comparatively low immunodepressive potential and that immune cells mediating natural host defence mechanisms appear especially resistant to this drug.
椭圆玫瑰树碱（2-甲基-9-羟基椭圆玫瑰树碱，9-HME）是一种最近显示具有临床抗肿瘤活性的化学物质，其免疫效应在小鼠中进行了研究。仅在静脉注射至少5mg/kg的单一药物剂量后处理时，对T细胞依赖性和T细胞非依赖性抗原的初次抗体反应、迟发型超敏反应性和对丝裂原的反应性才会显著降低，即这些剂量明显高于已知在同一物种中发挥完全抗肿瘤效力并诱导淋巴细胞耗竭的剂量。只有LD50范围内的药物剂量（即10mg/kg）会降低NK细胞和活化巨噬细胞对肿瘤靶细胞表达非特异性细胞毒性的能力。当使用重复给药方案时，在高于显示化疗活性的剂量下再次观察到明显的免疫抑制。所获得的数据表明，在化疗有效剂量下，9-HME在小鼠中具有相对较低的免疫抑制潜力，并且介导天然宿主防御机制的免疫细胞似乎对这种药物具有特别的抗性。
